COX-2、Ki-67与乳腺癌新辅助化疗疗效的关系

Correlation between expression of COX-2,Ki-67 and neoadjuvant chemotherapy in breast cancer

目的 研究COX-2、Ki-67在乳腺癌新辅助化疗前后的表达变化及其与新辅助化疗疗效的关系。方法 应用免疫组织化学法检测48例乳腺癌新辅助化疗前后标本中COX-2、Ki-67的表达。结果新辅助化疗总有效率为70．8％，总临床获益率为95．8％。化疗前后COX-2阳性率、Ki-67指数变化显著，分别由化疗前的62．5％和（46．81±23．17）％，降到化疗后的41．7％和（33．23±18．11）％，P〈0．05。化疗前后COX-2阳性的乳腺癌组织中Ki-67指数均显著高于COX-2阴性者，P〈0．01。新辅助化疗后COX-2表达阳性者，化疗效果差（P〈0．05）；而Ki-67高表达者总有效率高于低表达者（P〈0．05）。结论 COX-2、Ki-67可作为指导乳腺癌新辅助化疗并预测化疗敏感性的分子生物学指标。

Objective To study the correlation between expression of COX-2, Ki-67 and neoadjuvant chemotherapy in breast cancer. Method COX-2 and Ki-67 were examined by immunohistochemical staining in 48 breast cancer samples. Results The overall response rate and clinical benefit rate to neoadjuvant chemotherapy were 70.8% and 95.8% ,respectively. The expression of COX-2 and Ki-67 after the chemotherapy [41.7% and （33.23 ± 18.11）% ] was significantly lower than those in prechemotherapy [62.5% and （46.81 ± 23.17）%], P〈 0.05. Ki-67 index was higher in COX-2 positive tumors than that in the COX-2 negative ones before and after neoadjuvant chemotherapy, P 〈 0.01. The effect of neoadjuvant chemotherapy had a significantly negative correlation with COX-2 expression. Patients with high expression of Ki-67 were more likely to respond to treatment. Conclusion The expression of COX-2 and KI-67 as molecular markers could be a guide for chemotherapy and prediction for neoadjuvant＇s response to chemotherapy in breast cancer.